Skip to main content

Table 1 Patients' main characteristics

From: Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

 

All

Patients who

underwent surgery

Patients who

were operated

Characteristics

N

%

N

%

N

%

 

25

 

9

 

16

 

Age

      

Median

(range)

65.5

(39.8-80.5)

 

60.0

(39.8-80.5)

 

69.7

(40.7-81.9)

 

Gender

      

   Male

16

64%

6

67%

10

63%

   Female

9

36%

3

33%

6

38%

Tumor location

     

0%

   Stomach

4

16%

1

11%

3

19%

   Small intestine

7

28%

4

44%

3

19%

   Peritoneum

7

28%

1

11%

6

38%

   Oesophagus

2

8%

0

0%

2

13%

   Rectum

4

16%

3

33%

1

6%

   Pelvis

1

4%

0

0%

1

6%

Tumor size (mm)

      

   Median (range)

150

(36-280)

150

(45-280)

149

(36-200)

   ≤ 50

2

8%

1

11%

1

6%

   50 < - ≤ 100

7

28%

3

33%

4

25%

   > 100

16

64%

5

56%

11

69%

WHO PS

     

0%

   0

10

40%

4

44%

6

38%

   1

10

40%

5

56%

5

31%

   2

2

8%

0

0%

2

13%

   3

1

4%

0

0%

1

6%

   Not reported

2

8%

0

0%

2

13%

Best response to IM

      

   PR

15

60%

6

67%

9

56%

   SD

7

28%

2

22%

5

31%

   PD

3

12%

1

11%

2

13%